Expertise in
14
conditions

Dr. William T. Cash

Hematology | Oncology
Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, 
Atlanta, GA 

Overview

William Cash is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia.

Dr. Cash is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Neuroblastoma, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

He is actively involved in clinical research, participating in 31 clinical trials. Dr. Cash is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in GA

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

Arthur M. Blank Hospital
2220 N Druid Hills Rd NE, Atlanta, GA 30329

Additional Areas of Focus

Dr. Cash has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug
Study Drugs: Larotrectinib, Larotrectinib Sulfate
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (6.1 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Referral may be required

Egleston Children's Hospital At Emory

1405 Clifton Rd NE, 
Atlanta, GA 
 (2.3 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lakshmanan Krishnamurti is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

Expertise in
15
conditions
Dr. Satheesh M. Chonat
Hematology | Oncology
Expertise in
15
conditions
Dr. Satheesh M. Chonat
Hematology | Oncology
Referral may be required

Arthur M. Blank Hospital

2220 N Druid Hills Rd NE, 
Atlanta, GA 
 (0.1 miles away)
404-785-1200
Languages Spoken:
English, Hindi, Kannada, Malayalam, Spanish, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Satheesh Chonat is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Chonat is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Hemolytic Anemia, Anemia, Hemolysis, Congenital Hemolytic Anemia, and Splenectomy. Dr. Chonat is currently accepting new patients.

Frequently Asked Questions about Dr. William T. Cash

How do I make an appointment with Dr. William T. Cash?

You can book an appointment with Dr. William T. Cash by calling their office at 404-785-1200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William T. Cash a top-rated expert for Hepatoblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William T. Cash is classified as an Advanced expert for Hepatoblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William T. Cash specialize in?

While Dr. William T. Cash is a Hematology, they have specific expertise in Hepatoblastoma, Neuroblastoma, and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. William T. Cash accept my insurance?

Dr. William T. Cash accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-785-1200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cash's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile